Filing Details
- Accession Number:
- 0000919574-25-001777
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-04 20:19:51
- Reporting Period:
- 2025-02-28
- Filing Date:
- 2025-03-04
- Accepted Time:
- 2025-03-04 20:19:51
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1162194 | Standard Biotools Inc. | LAB | Laboratory Analytical Instruments (3826) | 770513190 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1534260 | Casdin Partners Gp, Llc | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | Yes | No | Yes | No | |
1534261 | Casdin Capital, Llc | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | Yes | No | Yes | No | |
1534264 | Eli Casdin | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | Yes | No | Yes | No | |
1534265 | Casdin Partners Master Fund, L.p. | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | Yes | No | Yes | No | |
1823061 | Casdin Private Growth Equity Fund, L.p. | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | Yes | No | No | No | |
1864554 | Casdin Private Growth Equity Fund Gp, Llc | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | Yes | No | No | No | |
1891102 | Casdin Private Growth Equity Fund Ii, L.p. | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | Yes | No | No | No | |
1919480 | Casdin Private Growth Equity Fund Ii Gp, Llc | 1350 Avenue Of The Americas, Suite 2600 New York NY 10019 | Yes | No | No | No | |
2028254 | Casdin Amplify Fund, Lp | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-02-28 | 4,820,959 | $1.07 | 58,846,780 | No | 4 | P | Indirect | See footnote |
Common Stock | Acquisiton | 2025-02-28 | 545,000 | $1.07 | 59,391,780 | No | 4 | J | Indirect | See footnote |
Common Stock | Disposition | 2025-02-28 | 545,000 | $1.07 | 0 | No | 4 | J | Indirect | See footnote |
Common Stock | Acquisiton | 2025-02-28 | 58,215 | $1.07 | 2,806,470 | No | 4 | A | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See footnote |
No | 4 | J | Indirect | See footnote |
No | 4 | J | Indirect | See footnote |
No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 13,939,637 | Indirect | See footnote |
Common Stock | 2,744,219 | Indirect | See footnote |
Footnotes
- The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
- Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund.
- The securities were owned directly by Amplify and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
- Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date.
- The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $62,000 in cash compensation for services as a board member.
- Includes RSUs.
- The securities are owned directly by Eli Casdin.
- The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
- The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.